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Background: Alzheimer disease is a multifactorial disorder characterized by the progressive deterioration of
neuronal networks. The pathological hallmarks includes extracellular amyloid plaques and intraneuronal
neurofibrillary tangles, but the primary cause is only partially understood. Thus, there is growing interest in
developing agents that might target multiple mechanisms leading to neuronal degeneration. CHF5074 is a
nonsteroidal anti-inflammatory derivative that has been shown to behave as a γ-secretase modulator in vitro and to
inhibit plaque deposition and to reverse memory deficit in vivo in transgenic mouse models of Alzheimer’s disease
(AD). In the present study, the effects of a long-term (13-month) treatment with CHF5074 on indicators of brain
functionality and neurodegeneration in transgenic AD mice (Tg2576) have been assessed and compared with those
induced by a prototypical γ-secretase inhibitor (DAPT).
Results: To this end, plaque-free, 6-month-old Tg2576 mice and wild-type littermates were fed with a diet
containing CHF5074 (125 and 375 ppm/day), DAPT (375 ppm/day) or vehicle for 13 months. The measured
indicators included object recognition memory, amyloid burden, brain oligomeric and plasma Aβ levels,
intraneuronal Aβ, dendritic spine density/morphology, neuronal cyclin A positivity and activated microglia. Tg2576
mice fed with standard diet displayed an impairment of recognition memory. This deficit was completely reverted
by the higher dose of CHF5074, while no effects were observed in DAPT-treated mice. Similarly, amyloid plaque
burden, microglia activation and aberrant cell cycle events were significantly affected by CHF5074, but not DAPT,
treatment. Both CHF5074 and DAPT reduced intraneuronal Aβ content, also increasing Aβ40 and Aβ42 plasma
levels.
Conclusions: This comparative analysis revealed a profoundly diverse range of clinically relevant effects
differentiating the multifunctional anti-inflammatory derivative CHF5074 from the γ-secretase inhibitor DAPT and
highlighted unique mechanisms and potential targets that may be crucial for neuroprotection in mouse models
of AD.
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Extracellular amyloid plaques formed by aggregated
β-amyloid (Aβ) peptides and intracellular neurofibrillary
tangles are the landmarks of Alzheimer’s disease (AD)
pathology [1]. Studies relying on familial AD patients with
mutations in the Aβ (amyloid) precursor protein APP, or
the catalytic subunits of the γ-secretase complex respon-
sible for the second (Aβ-generating) step of APP process-
ing yielded the so-called “β-amyloid cascade hypothesis”
of AD. Recently, this etiopathogenetic hypothesis, which
in its latest formulation holds Aβ oligomers as the most
proximal cause of AD neurodegeneration [2], is facing the
failure of multiple clinical trials carried out with various
drugs targeting Aβ accumulation in the brain [3]. These
include active and passive anti-Aβ vaccines, but also
γ-secretase inhibitors and modulators, and Aβ aggregation
inhibitors [4-7]. Additional abnormalities not so closely
related to Aβ accumulation/overproduction per se (e.g.
altered intraneuronal APP metabolism and trafficking)
[8-10] and other derailed cellular processes whose precise
causal relationship with Aβ remains to be elucidated, have
been described in the AD brain. The multifaceted cellular
dysregulation associated with AD neurodegeneration, pos-
sibly also leading to cortical atrophy, includes tau protein
hyperphosphorylation, neuronal cell death, neuroinflam-
mation, neurite abnormalities, synapse and dendritic spine
loss [10-16]. Thus, the search for new (and effective) AD
therapies needs to address additional targets other than
just amyloid clearance and to focus on early prevention of
neurodegeneration.
CHF5074 [1-(3′,4′-dichloro-2-fluoro[1,1′-biphenyl]-4-
yl)-cyclopropanecarboxylic acid] is a nonsteroidal
anti-inflammatory derivative devoid of cyclooxygenase in-
hibitory activity. In vitro, CHF5074 behaves as a γ secretase
modulator preferentially inhibiting Aβ42 production, with-
out affecting neither the processing of the C-terminal por-
tion of APP, nor γ-secretase-mediated Notch processing
[17-19]. CHF5074 has been shown to inhibit brain plaque
deposition and to attenuate or reverse contextual and
spatial memory deficit in different transgenic mouse
models of AD, also reversing long-term potentiation deficit
in the hippocampus [20-22]. However, recent data have
shown that CHF5074 is able to promote axon growth and
astrocyte plasticity by modulating Rho-GTPase-dependent
signaling [23], thus suggesting that the range of biological
actions exerted by this compound may be wider than
expected. In the present in vivo and ex-vivo study, we eval-
uated the effect of a long-term treatment with CHF5074
on cognitive performance and on several neuronal dys-
function markers in the Tg2576 mouse model of AD. The
effects of CHF5074 were compared with those of DAPT
(N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine
t-butyl ester), a prototypical γ-secretase inhibitor [24].
Drug treatments were started at 6 months of age whenno plaques are detectable [25], and were carried on in a
chronic fashion till a very late age (19 months), which is
close to the life expectancy of Tg2576 mice. A recogni-
tion memory test was carried out before the analysis of




Tg2576 transgenic mice carry a transgene coding for the
695-amino acid isoform of human APP derived from a
large Swedish family with early-onset AD [25]. These mice
express high concentrations of the mutant Aβ, develop sig-
nificant number of amyloid plaques and display memory
deficits. Tg2576 mice and their non-transgenic littermates
(001349-W), which served as controls, were purchased
from Taconic Europe (Lille Skensved, Denmark). Mice
were all genotyped for retinal degeneration.
Six-months-old transgenic females and aged-matched
non-transgenic littermates were used. Transgenic and non-
transgenic mice (N = 17–27 per treatment group) were
treated for 13 months with CHF5074 (125 and 375 ppm in
the diet), DAPT (375 ppm/day in the diet) or standard diet
(herafter designated as “vehicle”). CHF5074- and DAPT-
medicated diets were provided by Mucedola (Settimo Mil-
anese, Italy). The estimated ingested doses of CHF5074
were about 20 and 60 mg/kg/day (behaviourally effective
dose when given chronically for 9 months) [21]; the esti-
mated ingested dose of DAPT was about 60 mg/kg/day.
The dose of DAPT was selected based on previous studies
showing that the drug given orally at doses ranging from
10 to 100 mg/kg dose-dependently inhibited cortical Aβ
levels in hAPP transgenic mice [26]. After behavioural test-
ing, mice were sacrificed and their brains were split in the
two hemispheres. The left hemisphere was divided into an-
terior and posterior parts at level −0.70 according to the
Paxinos and Franklin atlas of the mouse brain [27]. The
anterior part, containing the olfactory bulb, was quickly
frozen into liquid N2, while the posterior part, including
the hippocampus, was fixed for amyloid plaque and Aβ
oligomer analysis. The right hemisphere was divided as
above and fixed for immunohistochemistry (anterior part)
and Golgi-Cox staining (posterior part, including the
hippocampus). Animal care and treatments were in ac-
cordance with the EU Directive 2010/63/EU for animal ex-
periments and in conformity with protocols approved by
the Ethical Committee of Animal Experimentation, Univer-
sity of Bologna.
Novel object recognition test (NOR)
Long-term memory was evaluated in 18 months-old
mice using NOR, measuring recognition memory under
spontaneous behavioural conditions. Before NOR, all
animals were tested for the papillary reflex and only
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tested in an open-square grey arena (46 x 46 cm), 30 cm
high (Ugo Basile, Comerio, Italy). The task started with
a habituation trial in which the animals were placed into
the empty arena for 10 min. The next day, mice were
placed into the same arena containing two identical ob-
jects (familiarization phase). In order to evidence side
preferences, exploring times spent on left and right fa-
miliar objects were recorded separately. The exploratory
behaviour was analyzed by calculating the investigation
time on both objects. Sniffing and touching the object at
a distance not greater than 2 cm were scored as object
investigation. Four hours later (test trial) mice were
placed in the arena containing one object identical to
the one presented during the familiarization phase (fa-
miliar object), and a new one (novel object); the time
spent exploring the two objects was recorded for
10 min. The videotracking software AnyMaze (Stoelting,
Wood Dale, Illinois) was used for analysis. Memory was
expressed as recognition index: (seconds on novel – sec-
onds on familiar)/(total time on objects). Animals with
no memory impairment spent longer time investigating
the novel object, giving a higher discrimination index.
Golgi-Cox staining
FD Rapid GolgiStain™ Kit (FD NeuroTechnologies,
Ellicott City, MD, USA) was used for detailed morpho-
logical analysis of dendritic spines. Tissue was rapidly
frozen, cut on a cryostat and mounted on gelatin-coated
microscope slides. Sections were processed with the
NDT104 FD Rapid GolgiStain™ Kit. For each mouse,
ten fully impregnated hippocampal CA1 neurons were
identified under low magnification (20×, 0.5NA). The
acceptance criteria for spines were according to Middei
et al. [28]. Dendritic spines were measured under high
magnification (100×, 1.25NA) from images acquired
using a digital camera (Olympus F-View). Measurements
were performed on secondary and tertiary branches of
CA1 basal dendrites irrespective of their orientation. On
each neuron, at least five dendritic spines were selected
according to the criteria proposed by Knafo et al. [29]:
only considering spines separated throughout their entire
length from neighbour spines or dendrites and excluding
spine-like protrusions with bifurcated heads or with heads
longer than 3.5 μm. Spine length was defined as the dis-
tance from the dendritic shaft to the tip of the spine.
Immunohistochemistry and image analysis
Indirect immunofluorescence was used to determine im-
munoreactivity associated with intracellular Aβ, cyclin A,
NeuN. Brain tissue was immersed in 4% paraformaldehyde
for 24 hours and then washed in 5% sucrose in phosphate
buffer. Sections (14 μm thick) were cut with a cryostat to
include the medial cortex. The following primaryantibodies were used: 6E10 anti-Aβ1–16 monoclonal anti-
body (Covance, Princeton, NJ) for APP/Aβ (this antibody
reacts with the sAPPβ precursor as well as with the
processed forms of Aβ) at a 1:1000 dilution; 4G8 anti-Aβ
17–24 monoclonal antibody (Covance) for APP/Aβ (this
antibody reacts with the sAPPβ precursor as well as with
the processed forms of Aβ) at a 1:800 dilution; rabbit anti
Cyclin A (ab7956, AbCam, Cambridge, UK) diluted 1:200;
mouse anti neuronal nuclei antibody (NeuN, MAB377
Chemicon) diluted 1:200. Appropriate Rhodamine Red-
X-and FITC-conjugated secondary antibodies were used
for detection (Jackson ImmunoResearch, Baltimore, PA).
For intraneuronal Aβ immunostaining, about 50 neu-
rons in the anterior cingulated cortex were analyzed for
each animal. Stained specimens were analyzed with a
Nikon 600 Eclipse microscope equipped with a Nikon
DXM1200F digital camera (Nikon Italia, Florence, Italy).
The ProPlus software (Media Cybernetics Inc, Bethesda,
MD) was used to evaluate optical density in single cells.
The expression of cell cycle proteins was analyzed in
two sections/animal, in both genotypes. NeuN-positive
cells were scored within layers II/III of the frontal cor-
tex, and the percentage of cyclinA immunoreactive,
NeuN-positive cells was recorded [30]. For all markers,
the mean value/animal was used for statistical analysis.
All analyses were performed in a blinded manner.
Brain β-amyloid plaques and activated microglia
Brain samples corresponding to the posterior half of the
left hemisphere were used for quantitative analysis of
plaques and activated microglia. They were fixed in 10%
formalin and then embedded in paraffin according to
a standard procedure. Coronal sections (10 μm thick)
ranged from bregma −1.46 mm (anterior) to −2.06 mm
(posterior) [27]. Aβ plaque immunohistochemistry was
performed using the biotinylated 6E10 monoclonal anti-
body (Signet Laboratories, Dedham, MA) diluted 1.250
as primary antibody. Pretreatments were: incubation in a
3% H2O2 solution in distilled water for 15 minutes to
block endogenous peroxidase; incubation in 80% formic
acid for 30 minutes for antigen retrieval. After rinsing in
TBS for 10 minutes, sections were incubated overnight
at 4°C in a humid atmosphere with the primary antibody
diluted in TBS containing 0.3% Triton X-100. After rins-
ing in TBS for 10 min, sections were incubated for
60 min in a humid atmosphere with the streptavidin-
peroxidase solution, according to the mouse-on-mouse kit
procedure (Dako Cytomation, Glostrup, Denmark) using a
peroxidase-based revealing system. Peroxidase activity was
detected by treatment with 3,3′-diaminobenzidine (DAB)
for 5 minutes. Slides were photographed using a digital
Nikon DS microscope colour camera. Digital images were
analyzed using NIS-Elements software (Nikon, Tokyo,
Japan). Each image was analyzed using the automated
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with a target area size of 68,000 μm2. The software deter-
mined the number of plaques, the plaque mean area and
the plaque area fraction (immunopositive area/total area
used as scan object). Twelve counts were performed for
each of the two levels considered. Analyses were
performed in analogous areas of the cortex and hippocam-
pus using a 10x objective.
Activated microglia in CA1 region of hippocampus
was immunodetected using the Iba1 Rabbit polyclonal
antibody (Biocare, Concord, CA). A 20x objective and a
target area of 16,900 μm2 was used for this analysis,
which involved three counts in homologous areas of
CA1 region of hippocampus. After rinsing in distilled
water, sections were incubated in a 3% H2O2 solution in
distilled water for 15 minutes. After rinsing in TBS for
10 minutes, sections were incubated for 30 minutes with
normal goat serum diluted 1:20 with TBS. The sections
were then incubated overnight at 4°C in a humid atmos-
phere with the primary Iba1 antibody diluted 1:250 with
TBS. After rinsing in TBS for 10 min, sections were in-
cubated for 60 min in a humid atmosphere with the sec-
ondary antibody solution provided by the Goat anti
Rabbit Envision System (Dako, Denmark) diluted 1:1
with TBS. Peroxidase activity was detected by treatment
with DAB.
Brain Aβ oligomers
Aβ oligomers were determined in low-detergent (0.1%
Triton-X100, 0.01% Nonidet-P40) and high-detergent
(3% SDS, 0.5% Triton X-100, 1% deoxycholate) extracts
prepared from left hemi-forebrains specimens as de-
scribed by Lesné et al. [31] with slight modifications.
These included cumulative extraction (50 mM Tris–
HCl, pH 7.6, 150 mM NaCl, 2 mM EDTA, 0.01% NP40,
0.1% Triton X-100, plus 1 mM phenylmethylsulfonyl
fluoride) and mixing of the soluble (extracellular-
enriched) and cytoplasmic fractions, and the omission of
the endogenous immunoglobulin depletion step in order
to avoid any artefactual modification of the samples. The
residual pellet remaining after low-detergent extraction
was further extracted by gentle agitation in 200 μl of a
buffer solution containing 50 mM Tris–HCl (pH 7.4),
150 mM NaCl, 0.5% Triton X-100, 1 mM EDTA, 3%
SDS, 1% deoxycholate and 1 mM PMSF, followed by
centrifugation for 90 min at 13,000 rpm. Total protein
content of each extract was determined in triplicate with
the Bradford Protein Assay reagent (Bio-Rad) using bo-
vine serum albumin as standard; the average of the
resulting values (differing by less than 5% of the mean)
was used to balance sample input for immunoblot ana-
lysis. All extractions were performed in three experimen-
tal sessions, carried out at three-days intervals on
randomized subsets of the various brain samples, andthe resulting extracts (a total of 65) were flash-frozen in
dry ice and stored at −80°C. For immunoelectrophoretic
analysis, brain extracts (100 μg or 50 μg total protein/
each for the low-detergent and the high-detergent ex-
tracts, respectively) were heated for 15 min at 70°C in
sample buffer and electrophoresed on pre-cast 4-12%
Bis-Tris Midi gradient gels (Invitrogen). Gel-fractionated
proteins were electro-transferred to 0.2 μm nitrocel-
lulose membranes, which were boiled for 25 sec in
PBS, soaked for 10 min in PBS containing 100 mM
β-mercaptoethanol and 0.1% SDS, washed three times
(10 min each) with PBS and blocked with 5% bovine
serum albumin in Tris-buffered saline, prior to antibody
addition and incubation using the Snap i.d. blotting sys-
tem (Millipore). The 6E10 monoclonal antibody (diluted
1:500) was used for immunodetection. Antigen-antibody
complexes were revealed with a goat anti-mouse, IrDye
680-labeled secondary antibody (LI-COR; diluted 1:3000),
followed by visualization and quantification of immune-
reactive bands by near-infrared fluorescence with an
Odyssey imager (LI-COR). A total of 14 independent sets
of analyses, each comprising 10 sample extracts with
at least one vehicle-treated wild-type control, were per-
formed. Non-specific, 6E10 mAb cross-reactive polypep-
tides, present in both wild-type and Tg2576 brain extracts,
were used as loading controls and internal references
for data normalization. Synthetic prefibrillar Aβ42(n) pre-
pared according to Lambert et al. [32], with n-values
ranging from 1 to 4, was used as size standard for electro-
phoretic analysis. Results, expressed as NIRF arbitrary
units, were analyzed with the SigmaStat™ software and are
presented as mean ± standard error of the mean (SEM).
Aβ40 and Aβ42 plasma levels
At the time of sacrifice, blood samples were collected in
EDTA-vacuum collection tubes, centrifuged at 4000 g
for 10 min and plasma aliquots were stored at −80°C.
Simultaneous quantification of β-amyloid1-40 (Aβ40) and
β-amyloid1-42 (Aβ42) peptides was performed on prop-
erly diluted plasma samples using the INNO-BIA plasma
Aß forms kit (Innogenetics NV, Gent, Belgium, through
Innogenetics srl, Italy), following the manufacturer’s
instructions. This kit is a fluorimetric bead-based im-
munoassay using Luminex xMAPW technology. Briefly,
the Aβ40 and Aβ42 peptides are captured selectively by
a mix of beads (xMAPW microspheres) coated with three
monoclonal antibodies (mAb): 21 F12 for Aβ42, 2G3 for
Aβ40 and AT120 for matrix. Following an overnight
incubation step at 4°C, the mix is washed and subse-
quently incubated with the “detection conjugate” solution
(phycoerythrin-labeled streptavidin) at room temperature
for 1 h. The mix of beads is then washed and read using
the LuminexW 100™ IS Total System, which analyzes the









































Figure 1 Novel object recognition memory in the different
treatment groups. Bars represent the average (± SEM) of the
recognition index in the novel object recognition task. Vehicle-
treated Tg2576 mice showed a borderline significant impairment of
recognition compared to control non-transgenic mice treated with
vehicle (p = 0.052). CHF5074-treatment (375 ppm) completely
reversed memory impairment in Tg2576 mice (p = 0.031). DAPT was
ineffective both in Tg2576 and wild-type animals (wild type not
shown). The number of animals included in each group is indicated
under the corresponding bar. *p < 0.05 and # p = 0.052 vs vehicle-
treated Tg2576 mice.
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intensity units by a digital signal processor and then re-
lated to the concentration of the bound antigen through
the Luminex IS 2.3 software.
Statistical analysis
Data were analyzed with the appropriate model of analysis
of variance (ANOVA) depending on the type of variable.
Behavioural data were analyzed with two-way analysis of
variance with “genotype” (non-transgenic and Tg2576) and
“treatment” (vehicle, CHF5074/DAPT) as fixed factors and
mouse as random factor. For balanced design (object recog-
nition task), the ANOVA model also included “genotype by
treatment” as fixed factor. To reduce the loss of power due
to multiple testing post hoc comparisons were only directed
toward the transgenic control group (Tg2576-vehicle) and
were carried out with the Holm-Sidak’s test. Two-tailed
p values were calculated. Calculations were performed
with the statistical software SigmaStat™ (Version 3.5, SPSS,
Chicago, IL). Results were generally presented as mean ±
standard error of the mean (SEM).
Results
Drug tolerability
Total mortality during the 13 months-time period of the
present study was 28% and 15% for Tg2576 mice and
wild-type animals, respectively (Figure 1). Mortalities
in vehicle-, CHF5074 (375 ppm/day)- and DAPT
(375 ppm/day)-treated wild-type animals were 15%, 15%
and 30%, respectively. The corresponding values for
vehicle-, CHF5074 (125 ppm/day)-, CHF5074 (375 ppm/
day)- and DAPT (375 ppm/day)-treated Tg2576 mice
were 29%, 28%, 28% and 47%, respectively. Mortality
was not statistically different among treatment groups.
Overall, CHF5074 and DAPT, continuously administered
for 13 months, appeared to be well tolerated by both
wild-type and Tg2576 animals.
Object recognition memory performance of 18-months-old
Tg2576 mice chronically treated with CHF5074 or DAPT
Object recognition memory, measured by the novel object
recognition (NOR) task after 12 months of drug treatment,
was evaluated as a first indicator of CHF5074 efficacy. As
shown in Figure 1, compared to wild-type animals, Tg2576
mice fed with standard diet (“vehicle”) displayed a border-
line significant impairment of recognition memory (p =
0.052). This impairment was fully recovered in transgenic
animals chronically treated with the higher dose of
CHF5074 (375 ppm/day; p = 0.031), while it was not signifi-
cantly modified by the lower dose of CHF5074 (125 ppm/
day; p = 0.101). CHF5074 treatment did not affect recogni-
tion memory in wild-type mice. Chronic treatment with
DAPT (375 ppm/day) did not affect the NOR performance
of either wild-type (data not shown) or Tg2576 mice.Exploration time among the experimental groups was not
different in the training period (one way ANOVA, p = p =
0.365).
To exclude possible alterations of either motor or ex-
ploratory behaviour as possible influencing factors, the
mean speed re\corded during the 10 min habituation
trial in the empty arena, and the total object exploration
time during the familiarization phase were also analyzed.
Tg2576 mice treated with both doses of CHF5074
displayed a significant (p < 0.01) reduction in the mean
speed when compared to vehicle-treated mice (3.42 ± 0.64,
2.13 ± 0.24 and 2.19 ± 0.23 m/min after vehicle, CHF5074
125 and CHF5074 375 ppm/day, respectively). However,
this effect was not associated with significant differen-
ces in total time in movement (494 ± 26, 474 ± 28 and
511 ± 15 sec after vehicle, CHF5074 125 and 375 ppm/
day, respectively). Neither CHF5074 nor DAPT signifi-
cantly affected the mean speed (1.88 ± 0.18, 2.31 ± 0.18
and 1.72 ± 0.18 m/min after vehicle, CHF5074 375 ppm/
day and DAPT 375 ppm/day, respectively) or the to-
tal time in movement (470 ± 19, 514 ± 14 and 459 ± 20
sec after vehicle, CHF5074 375 ppm/day and DAPT
375 ppm/day, respectively) of wild-type animals.
Amyloid plaque burden, intraneuronal Aβ and Aβ
clearance in the brain of 18-months-old Tg2576 mice
chronically treated with CHF5074 or DAPT
Amyloid plaque burden was visualized with the anti-Aβ1–16










































































































































Figure 2 Effect of CHF5074 and DAPT treatments on Aβ-related, cellular and molecular parameters. Representative images of amyloid
plaques stained with the 6E10 monoclonal antibody in the cerebral cortex (A, C, E) and in the hippocampus (B, D, F) of untreated (vehicle, A, B)
and CHF5074-treated Tg2576 mice (C-F) are shown in the figure. CHF5074 dose and animal code number (#) are indicated in each panel.
Quantification of plaque immunostaining in both brain areas of untreated (“vehicle”), CHF5074-treated and DAPT-treated animals (indicated by the
different bar colours) is shown in panel G. Plasma Aβ40 and Aβ42 levels in the same groups of untreated, CHF5074- and DAPT-treated animals
are reported in panel H. The levels of monomeric Aβ and of different Aβ oligomeric species detected with the 6E10 antibody in low-detergent
(0.1% Triton-X100, 0.01% Nonidet-P40) and high-detergent (3% SDS, 0.5% Triton X-100, 1% deoxycholate) brain extracts are shown in panels I and
J, respectively. Data refer to the quantification of the indicated Tg2576-specific immunoreactive bands (i.e., polypeptides not present in brain
extracts from wild-type littermates) in untreated Tg2576 mice and in Tg2576 mice treated with CHF5074 or DAPT (same number of animals/
group as in panel G) by near-infrared fluorescence (NIRF; arbitrary units). Data in panels G-J are expressed as mean ± SEM; **p < 0.01 or *p < 0.05
vs vehicle-treated Tg2576 mice; the number of animals in each group is indicated below the corresponding bar (see Additional file 2: Figure S1
for a representative example of gel fractionation and immunoblot analysis).
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digital image analysis of coronal brain sections derived from
the cortex and the hippocampus (Figure 2G). CHF5074
treatment modified both the amount and the distribution
of amyloid plaques. Despite a higher plaque abundance in
the cortex compared to the hippocampus, at either dose it
caused a nearly 50% reduction of the plaque area fraction
in both brain regions. Quantification of the immunoreactiv-
ity revealed a significantly lowered plaque area fraction
in CHF5074-treated animals compared to control mice,
both in the cortex (−61.0 ± 5.1%, p < 0.001 and −48.2 ±
8.9%, p = 0.003 in the 125 and 375 ppm/day-treated groups,
respectively) and in the hippocampus (−52.3 ± 9.4%,
p = 0.007 and −64.9 ± 8.1%, p = 0.001 in the 125 and
375 ppm/day-treated groups, respectively). DAPT treat-
ment did not affect plaque burden.
In contrast, as further shown in Figure 2 (panels I, J),
no significant effect of CHF5074 treatment was observed
on brain Aβ oligomers (see Additional file 2: Figure S1
for a representative example of gel fractionation and im-
munoblot analysis). The only significant change revealed
by this analysis was an increase of brain monomeric Aβlevels in Tg2576 mice treated with the higher dose of
CHF5074, which was associated with increased plasma
levels of both Aβ40 and Aβ42 (Figure 2H). An even
higher increase of brain Aβ monomer levels was ob-
served upon treatment with DAPT, which also caused a
significant elevation of Aβ oligomeric species migrating
as dimers, trimers and nonamers, and a slight (border-
line significant) increase of 12-mers (Figure 2I, J).
Intraneuronal Aβ (APP) levels were assessed using
mAb 6E10 and 4G8 as detection reagent. Representative
images of brain cortex specimens stained using mAb
6E10 derived from untreated (panel A; “vehicle”) and
CHF5074-treated (panels B, C; 125 and 375 ppm) mice
are shown in Figure 3. A paper by Aho et al. [33] dir-
ectly compared all commercially available monoclonal
antibodies in post-mortem Alzheimer brain tissues, con-
cluding that intracellular labeling was readily apparent
when using 6E10 and that both 6E10 and 4G8 antibodies
failed to distinguish Aβ peptides from APP. Accor-
ding to these findings, we will use the term “6E10-
immunoreactivity” to describe the results obtained with




















































Figure 3 Effect of CHF5074 and DAPT treatments on 6E10
intraneuronal immunoreactivity. A-C. Representative images of
6E10-immunostaining of intraneuronal 6E10-immunoreactivity in
cerebral cortex sections of vehicle- (A), CHF5074 125 ppm- (B),
CHF5074 375 ppm- (C) and DAPT 375 ppm-treated Tg2576 mice (D);
# indicates the animal code. E. Quantification of intraneuronal
6E10-immunoreactivity in the different treatment groups. The
number of animals included in each group (N) is indicated under
the corresponding bar, data are expressed as mean ± SEM, *p < 0.05
and **p < 0.01 for CHF5074 treated vs untreated Tg2576 mice.
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sampled in the anterior cingulated cortex were used for
statistical analysis. As revealed by this analysis (Figure 3D),
6E10-immunoreactivity was significantly lower in Tg2576
mice treated with either dose of CHF5074 (−33.5 ± 7.3%,
p < 0.01; -27.1 ± 4.9%, p < 0.01) or DAPT (−44 + 10.6,
p < 0.01) than in vehicle-treated animals. The same results
were obtained using 4G8 antibody (data not shown).
Anti-neuroinflammatory properties and possible
downstream effects of chronic treatment with CHF5074
or DAPT
Microglia activation
Microglia activation was investigated with the use of an
antibody targeting the glia-specific calcium-binding adaptor
protein Iba1. Representative images of the hippocampal
CA1 region from vehicle- and CHF5074-treated transgenic
mice are shown in Figure 4 (panels A-D; Additional file 1:
Figure S2). Activated, immunopositive microglia was lower
(−66.3 ± 5.3% p < 0.001) in wild-type animals than in con-
trol, vehicle-treated Tg2576 mice. Interestingly, compared
to Tg2576 control mice, activated microglia in the hippo-
campus of CHF5074 (125 and 375 ppm/day)-treated
Tg2576 mice was significantly (p < 0.001) reduced (−50.2 ±
5.2% and −45.5 ± 4.5%, respectively). On the contrary,DAPT treatment did not affect activated microglia in
Tg2576 mice (+ 19.3 ± 18.0% increase).
Dendritic spine length and density
Dendritic spine length and density were next evaluated
in hippocampal pyramidal neurons of the CA1/CA2
fields by GolgiCox silver impregnation. As shown in
Figure 5, a reduction of spine density compared to age-
matched wild-type animals (p < 0.001) was apparent in
the hippocampus of vehicle-treated, control Tg2576
mice. In contrast, no significant difference in hippocam-
pal spine length was observed between wild-type and
transgenic animals (data not shown). While DAPT fully
prevented dendritic spine density reduction in Tg2576
mice, a clear and statistically significant amelioration ef-
fect of CHF5074 (p = 0.046 compared to vehicle-treated
transgenic animals) was only observed at the lower dose
(125 ppm/day) of the compound.
Cell cycle functionality
Cell cycle functionality was then investigated in mature
neurons by monitoring the levels of a regulatory mol-
ecule such as cyclin A (CycA), detected by immuno-
staining of neuronal nuclei (NeuN). Representative
images from vehicle (A-C) and CHF5074-treated Tg2576
mice (D-F) are reported in Figure 6, where panels B and
E refer to CycA, panels C and F to NeuN and panels A
and D to the merged images. The fraction of CycA-
positive cells over the total number of NeuN-positive
neurons was counted in layers II-III of the medial cere-
bral cortex. In wild-type and Tg2576 control mice the
percentage of CycA-expressing neurons was 8.6 ± 1.5%
and 47.8 ± 3.3%, respectively. As shown in Figure 6G, at
both 125 and 375 ppm/day doses, CHF5074 reduced the
percentage of CycA-positive neurons (17.6 ± 1.5% and
17.8 ± 1.3%, respectively; p < 0.001 vs vehicle-treated
control Tg2576 mice). DAPT treatment was less effective
than CHF5074 in reducing the percentage of CycA-
positive neurons (p < 0.05), leaving an average 35% of
neurons still positive to CycA immunostaining (Figure 6,
panel G).
Discussion
Age is a major risk factor for AD and various patho-
physiological changes, not all directly related to Aβ ac-
cumulation, take place in the ageing brain. Thus, when
assessing the preclinical therapeutic efficacy of a candi-
date AD modifying drug, it is of the utmost importance
that multiple indicators of brain functionality are exam-
ined in animal models of AD at the latest possible age.
Furthermore, as most AD-associated changes tend to be
irreversible, treatment should be started at a relatively
early age, when no (or very few) symptoms of disease
are detectable, and carried on in a chronic fashion till
Figure 4 Effect of CHF5074 and DAPT treatments on microglia activation. A-D. Representative images of Iba1-immunostaining of activated
microglia in hippocampus sections from wild-type (A) and Tg2576 vehicle- (B) and CHF5074-(C, D)-treated animals; # indicates the animal code.
E. Quantification of Iba1-immunostaining of activated microglia in the different treatment groups. CHF5074, but not DAPT, reduces the level of
microglial activation observed in Tg2576 mice. **p < 0.01 vs vehicle-treated Tg2576 mice.
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http://www.biomedcentral.com/1471-2202/14/44very late age (i.e. under conditions in which drug toler-
ability and lack of detrimental side-effects may become
a major concern). Based on this background, in the
present study the effects of chronic treatments with the
nonsteroidal anti-inflammatory γ-secretase modulating
compound CHF5074 or the γ-secretase blocker com-
pound DAPT on cognitive performance as well as on
several distinct post-mortem indicators of brain func-
tionality and neurodegeneration have been compared in
a transgenic mouse model of AD.
The present findings indicate that CHF5074, continu-
ously administered for 13 months at 125 and 375 ppm/day
doses, appears to be well tolerated by both wild-type and
Tg2576 animals. In line with this observation, CHF5074,
which is under development for the prevention and treat-
ment of AD, displayed a safe and well tolerated profile, as
established in an ascending dose regimens, double-blind,
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Figure 5 Effect of CHF5074 and DAPT treatments on dendritic spine d
mag of CA1 hippocampal cortex (A) visualized by the Golgi-Cox technique
hippocampal pyramidal neurons of wild-type (B), Tg2576 vehicle- (C), Tg25
ppm- (F) treated mice. G. Quantification of the data, including those relate
length of pyramidal neurons from the cerebral cortex of animals belonging
this analysis is indicated below the bars corresponding to each treatment gvariance with γ-secretase blockers, here typified by DAPT
(but see also e.g., [35]), no trends towards deleterious
effects across different dosing cohorts on both “paper and
pencil” and computerized cognitive tests have been de-
scribed so far for CHF5074 [36].
Previous studies indicated that CHF5074 treatment
may attenuate or reverse contextual memory deficit
when given acutely [22] or chronically (8-month treat-
ment) [21] to young Tg2576 mice. A reduction of spatial
memory deficit was similarly observed following chronic
treatment in a different mouse model of AD (TADS-41)
[19]. A reversal of object recognition memory as well as
hippocampal plasticity deficits was also observed upon
CHF5074 subchronic treatment of young Tg2576 mice
[22]. In this study we extended these observations
by demonstrating the efficacy of a further prolonged
(13 months) treatment with CHF5074 (375 ppm/day) in

























ensity and length in hippocampal pyramidal neurons. Low-power
; B-E: high-power mag (100x, 1.35NA) of spine morphology in
76 CHF5074 125 ppm- (D), CHF5074 375 ppm- (E) and DAPT 375
d to DAPT treatment, expressed as mean (± SEM) spine density and
to different experimental groups; the number of animals utilized for
roup. *p < 0.05; **p < 0.01. Bars: A, 200 μm; B, 5 μm.
Figure 6 Effect of CHF5074 and DAPT treatments on neuronal cell-cycle functionality. A-F. Representative images of cyclin A
immunoreactivity (red staining, B and E) in NeuN-positive cells (green staining, C and F) and of the resulting merge images (A, D) in Tg2576-mice
treated with vehicle (A-C) or with CHF5074 375 ppm (D-F); # indicates the animal code. G. Quantification of cyclin-A positive cells versus total
NeuN-positive cells in the different treatment groups. While approximately 50% of neurons express Cyclin A in untreated (“vehicle”) Tg2576 mice,
the percentage of Cyclin A/NeuN-positive neurons is reduced to less than 20% in CHF5074-treated, but not DAPT-treated, animals. * p < 0.05
and ***p < 0.001 vs vehicle-treated Tg2576 mice; c p < 0.001 vs CHF5074 125 and 375 ppm-treated Tg2576 mice.
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taneous animal behavior and does not require any ex-
ogenously applied stress, is widely used for memory
evaluation in mouse models of AD [37-39]. To our
knowledge, no previous study has evaluated the potential
efficacy of a candidate AD drug in preventing cognitive
deficit at such a late stage of animal life. This finding
opens up the possibility that CHF5074 could be benefi-
cial in reducing cognitive impairment also in late AD
provided that treatment is started relatively early in the
course of illness. Under the same experimental condi-
tions, DAPT was ineffective in improving visual memory
performance. This finding is in line with the previously
observed failure of γ-secretase inhibition to rescue object
recognition deficits in APP-overexpressing mice [40]
and suggests that some cellular and molecular parame-
ters are differentially affected by CHF5074 and DAPT.
This view is further supported by the differential re-
sponses of some main pathology markers observed in
Tg2576 mice treated with CHF5074 or DAPT (summa-
rized in Table 1).Four of the biochemical indicators analyzed in the
present study directly bear on Aβ and its brain accu-
mulation/mobilization. These include amyloid burden,
brain Aβ oligomers, plasma Aβ and intraneuronal APP/
Aβ levels. Amyloid burden was markedly reduced in
CHF5074-, but not in DAPT-treated animals. On the con-
trary, intraneuronal APP/Aβ and plasma levels of Aβ40
and Aβ42 were similarly modified by both treatments.
The increase of plasma Aβ levels observed after chronic
treatment with DAPT appears paradoxical. Although the
effects of chronic treatment with DAPT on plasma or
brain Aβ levels are not known, it has been observed that
treatment of transgenic mice and humans with other
gamma-secretase inhibitors (e.g., semagacestat) may cause
late rebound effects on plasma Aβ levels [41]. Both
CHF5074 and DAPT did not affect Aβ oligomers, either
in high-detergent (membrane/intracellularly enriched) or
in low-detergent (extracellularly enriched) brain extracts.
In the case of CHF5074, the only observed effect was a
small, but statistically significant increase in brain Aβ
monomers. This effect was magnified in Tg2576 mice
Table 1 Comparison between the main pathology markers in Tg2576 mice chronically treated either with a γ-secretase
inhibitor (DAPT) and a mixed γ-secretase modulator with anti-inflammatory properties (CHF5074)
Task/marker DAPT CHF5074
Novel object recognition test (recognition index) unchanged restored at wild-type level at 375ppm
amyloid plaque burden unchanged reduced
oligomers
plasma Aβ42 increased increased at 375ppm
intraneuronal Aβ reduced reduced
microglia activation (Iba1-IR) unchanged reduced
Dendritic spine density (CA1/2 pyramidal neurons) restored at wild-type level increased at 375ppm, compared to Tg2576 vehicle
Aberrant cell cycle events (cyclinA-IR neurons) lightly reduced (−28%) strongly reduced (−63%)
Treatments were started in 6month old rats and protracted for 13 months. Behavioral test was then carried out in 18month old animals, and all post-mortem
observation in 19month old animals.
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http://www.biomedcentral.com/1471-2202/14/44treated with DAPT, which also caused a statistically sig-
nificant increase of some Aβ oligomeric species. Although
the reason for this quite unexpected finding is presently
unclear, it is conceivable to imagine that given the ex-
tremely prolonged treatment duration time this may re-
flect the “Aβ rise” phenomenon previously observed with
DAPT and other γ-secretase inhibitors in the presence of
suboptimal inhibitor and/or CTFβ concentrations [42].
This point will be clarified in further studies by analyzing
accumulation of other γ-secretase substrates, like CTF,
p75, etc.
Aβ42-immunoreactivity was detected by single-neuron
microdensitometry using the 6E10 and 4G8 monoclonal
antibodies as probes. Since the peptide epitopes (AA 1–16)
targeted by 6E10 and 4G8 are shared by the Aβ42 and the
Aβ40 peptides as well as by the APP precursor and the
sAPPβ and CTFβ cleavage by-products, these antibody can
recognize all the above species [33]. Moreover, the possi-
bility that abnormally trafficked APP or CTFβ (but not
sAPPβ, which is extracellularly released) and other APP-
derived peptides like C99 [43] may also contribute to the
immunostaining observed in neurons from Tg2576 mice
cannot be ruled out at present. Increasing attention is
currently being paid to intraneuronal Aβ, generated via
the endosomal system and accumulated in endosomes/
lysosomes, mitochondria and autophagosomes, as an
early player in the pathogenesis of AD [10]. In fact,
intraneuronal Aβ accumulation occurs well before the in-
crease of extracellular Aβ [10], it is detectable in plaque-
free animals [22], and converging reports indicate a key
pathogenetic role of intraneuronal β-amyloid in neuro-
degeneration and AD pathology [44,45]. For example, the
intracellular concentration of Aβ42, the most toxic Aβ
variant, in pyramidal (CA1) human neurons has been esti-
mated to be 3 μM in the case of sporadic AD patients,
as compared to 660 nM in the case of neurons from con-
trol, unaffected subjects [46]. Intraneuronal Aβ severely
affects neurons viability [8,9,47] and vulnerability to va-
rious neurotoxic challenges [48]. Also, elevated levels ofintraneuronal Aβ42 have been reported to be causally re-
lated to the activation of the protein kinases that are re-
sponsible for intracellular tau hyperphosphorylation in
early stages of the disease [49,50]. Moreover, intraneuronal
Aβ accumulation has been shown to play a key role in syn-
apse loss and dysfunction [10,51]. CHF5074 was previously
shown to restore the levels of synaptophysin [21], to reduce
the accumulation of native hyperphosphorylated tau, and
to decrease brain GSK-3β levels, a secondary effect pre-
sumably associated with the reduction of intraneuronal Aβ
[52], thus suggesting an effect of this molecule on the most
relevant molecular players involved in AD pathology.
In both CHF5074- and DAPT-treated animals there
was a normalization of dendritic spine density in CA1/2
pyramidal neurons compared to vehicle-treated Tg2576
mice. With the use of two-photon confocal microscopy,
DAPT has recently been shown to reduce dendritic
spine density when administered acutely to wild-type
mice [53]. It should be noted, however, that pharmaco-
logical modulation of wild-type and mutated-APP are
quite different [54] and that the effect of APP on den-
dritic spine number is still highly controversial [55].
Moreover, multiple and diverse events, such as intracel-
lular soluble or extracellular fibrillar Aβ levels, or the
combination of intracellular soluble Aβ and hyper-
phosphorylated tau, can lead to dendritic spine loss [56].
Thus, amyloid clearance from neurons and from the
brain by CHF5074 and DAPT may positively affect
structural aspects of hippocampal circuits (e.g., dendritic
spine density), but this is not enough, per se, to sustain
cognitive performance, as suggested by the divergent
effects of the two drugs on novel object recognition test.
Various dysfunctions, some of which precede cortical
atrophy and amyloid plaque deposition, are causally associ-
ated with AD neurodegeneration. These include neuro-
inflammation, neurite abnormalities leading to dendritic
spine loss, neuronal cell death and aberrant cell cycle
events. Epidemiological analyses support the notion that
intake of nonsteroidal anti-inflammatory drugs (NSAIDs)
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to this positive preventive trend, therapeutic studies testing
NSAID efficacy in AD patients have been largely unsuc-
cessful so far [57]. A possible explanation for these disap-
pointing, and apparently controversial results may be a
wrong therapeutic time-window. In fact, while the occur-
rence of plaque-dependent inflammation in AD has been
extensively documented in both human specimens and
transgenic animal models of the disease, clinical and ex-
perimental evidence for the occurrence of inflammation in
preclinical, asymptomatic phases of AD pathology are
scanty [58]. In transgenic mouse models of AD, cerebro-
vascular inflammation has been reported to occur before
plaque deposition [59] and various treatments targeting
neuroinflammation have been proved to be effective on
cognition maintenance or recovery [57]. Moreover, age-
dependently enhanced neuroinflammatory processes may
play an important role in neuronal death or dysfunction,
possibly inducing spine pathology [56] as well as cell cycle
alterations [30]. Thus, in the present study the possible
anti-neuroinflammatory properties of CHF5074 and DAPT
have also been assessed.
As revealed by the present results, while a substantial re-
duction of microglia activation was observed in CHF5074-
treated animals, no effect on Iba1 immunostaining was
detected following treatment with DAPT. Similar results
with CHF5074 were obtained in a previous shorter-term
study [21]. These data suggest that, at least under the
present experimental conditions, CHF5074, but not DAPT,
exerts an anti-neuroinflammatory activity. It should be
mentioned that while a partial γ-secretase inactivation has
a protective role on amyloid pathology and inflammation,
the genetic ablation of presenilin causes progressive inflam-
matory responses [60]. Thus, the modulatory γ-secretase
activity exerted by CHF5074 could positively affect initial
microglia activation, while blockage of γ-secretase activity
by DAPT is likely to be completely ineffective on this par-
ticular target. In line with this view, it has been reported
recently that inhibition of lipopolysaccharide-induced
γ-secretase activity by DAPT interferes with immune and
anti-inflammatory regulatory pathways in the brain [61],
while acute DAPT administration restraints microglia acti-
vation [62,63]. Recently, it has also been proposed that ibu-
profen and its derivatives, including CHF5074, besides
reducing Aβ pathology and neuroinflammation, modu-
late astrocyte reactivity through a Rho-GTPase/PAK/ERK-
dependent signalling pathway [23]. In keeping with this
purported mode of action, we have previously shown that
chronic treatment of Tg2576 mice with CHF5074 causes
astrocyte hypertrophy and their accumulation around large
Aβ deposits [21] -another mechanism that may contribute
to the neuroprotective and functional recovery effects pro-
moted by this compound. This result was also confirmed
in this study (Additional file 3: Figure S3). We alsoobserved that DAPT also upregulates GFAP-IR but not
Iba1, thus further suggesting that microglia activation is a
property of CHF5074.
The anti-neuroinflammatory action produced by chro-
nic treatment with CHF5074 may counteract cell death
caused by oxidative damage. Ectopic expression of cell
cycle proteins identifies neuronal populations undergo-
ing neurodegeneration [63-65] and aberrant cell cycle
events have been detected in Tg2576 mice starting from
6 months of age. Thus, the marked reduction of cyclin
A-positive neurons (from 48% to 18%) elicited by
CHF5074, but not DAPT, points to a fairly strong
neuroprotective effect of the former compound. The
mechanisms underlying cell-cycle re-entry and cell-cycle
protein expression in AD neurons are still obscure
[14,65]. It is worth noting, however, that alterations in
brain microglia have been shown to occur concomitantly
with the appearance of ectopic cell-cycle events and that
NSAIDs prevent, but do not reverse, neuronal cell cycle
re-entry in the R1.40 mouse model of AD [30]. The
treatment regimen utilized in this study strongly sup-
ports this conclusion. However, microglia activation and
neuroinflammation, are also triggered by intraneuronal
Aβ accumulation at an early stage of the disease [66]
and, conversely, inflammation negatively affects Aβ
efflux from the brain [67]. Thus, the anti-inflammatory
and cell cycle normalization properties of CHF5074
combined with its Aβ clearance-promoting effect may
explain the superior neuroprotective action of this com-
pound compared to DAPT.
Conclusion
The present findings suggest that chronic treatment of
Tg2576 mice with CHF5074, but not DAPT, effectively
prevents AD symptoms (e.g., plaque accumulation and
cognitive impairment) and positively affects various
neurodegeneration-related events, some of which may
occur earlier than, and be not directly linked to, massive
Aβ accumulation. The most significant of the latter ef-
fects are a marked quenching of microglia activation
and associated neuroinflammation as well as a reduced
frequency of anomalous cell cycle re-entry events in
affected neurons. Notably, the beneficial effects of
CHF5074 remain well detectable till an extremely late
age, after a one year-long chronic treatment. The multi-
modal action of CHF5074 appears to be in line with the
increasingly recognized multifactorial nature of AD
pathology, whose treatment can greatly benefit from the
ability of candidate therapeutic compounds to act on
more than one target [15,67]. Taken together, the results
of this extensive comparative analysis suggest that a spe-
cific subset of effects not so closely related to Aβ accu-
mulation and APP processing may play a crucial role
in dictating the outcome of neurodegeneration and
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notably the promotion of glia and neuronal cell cycle
homeostasis, may represent key targets for the develop-
ment and monitoring of second generation AD modify-
ing drugs.Additional files
Additional file 1: Figure S2. A, B: Representative images of activated
microglia (IBA1 immunostaining) of CA1 hippocampal cortex of Tg2576
vehicle (A) and DAPT (B) treated animals. C, D: Representative images of
6E10 immunostaining of cerebral cortex of Tg2576 vehicle (C) and DAPT
(D) treated animals.
Additional file 2: Figure S1. Representative example of SDS-PAGE
fractionation (4-12% Bis-Tris Midi gradient gel) and immunoblot analysis
(primary antibody: 6E10 mAb, 1:500; secondary antibody: goat anti-mouse,
IrDye 680-labeled antibody, 1:3000) carried out on “low-detergent”, 0.01%
NP40/0.1% SDS brain extracts (enriched in extracellular Aβ). Immune-
reactive bands were visualized by near-infrared fluorescence (Odyssey
imager, LI-COR). Non-specific, 6E10 mAb cross-reactive polypeptides (arrow),
present in both wild-type and Tg2576 brain extracts, were used as loading
controls and internal references for data normalization. Synthetic prefibrillar
Aβ42(n) prepared according to Lambert et al. [32], with n-values ranging
from 1 to 4 (not shown), was used as size standard for electrophoretic
analysis. Immune-reactive bands were quantified as “near-infrared
fluorescence” (NIRF) arbitrary units (see ‘Methods’ for additional details).
Additional file 3: Figure S3. Representative images of 6E10 (green)
and GFAP- (red) immonostaining in the cerebral cortex of Tg2576
vehicle- (A) and DAPT 375ppm- (B) treated animals. A large number of
plaques is observed in both groups, while the GFAP-immunostaining is
strongly up-regulated in treated animal. C. semiquantitative evaluation of
GFAP immunostaining in the experimental groups. The analysis was
performed by evaluating the percentage of plaques surrounded by
reactive astrocytes, as evaluated in an area doubling the plaque diameter
(see Imbimbo et al.2010, for details). Treated animals show an intense
upregulation of GFAP-immunostaining around the plaques. Statisical
analysi: one-way ANOVA and Dunnet’s post-hoc test. * p<0.05; **p<0.001.Competing interest
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